Vaccination against Nonmutated Neoantigens Induced in Recurrent and Future Tumors

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Targeting neoantigens for cancer vaccines faces challenges due to tumor specificity and patient variability.
• Current vaccination strategies are limited to patients whose tumors express specific neoantigens.

Purpose of the Study:

• To investigate a novel vaccination strategy targeting antigens induced by the downregulation of the peptide transporter associated with antigen processing (TAP).
• To evaluate the efficacy and applicability of this new strategy compared to traditional neoantigen-based vaccines.

Main Methods:

• Developing a vaccination strategy targeting antigens arising from TAP downregulation in tumor cells.
• Comparing the effectiveness and toxicity of TAP downregulation-induced antigen vaccination versus mutation-derived neoantigen vaccination in preclinical models.
• Assessing human CD8+ T cell responses to tumor cells with experimentally reduced TAP expression.

Main Results:

• Vaccination against TAP downregulation-induced antigens was more effective than vaccination against mutation-derived neoantigens.
• This novel vaccination strategy showed no measurable toxicity.
• The approach inhibited the growth of concurrent and future tumors in models of recurrence and premalignant disease.
• Human CD8+ T cells stimulated with TAP-low dendritic cells recognized tumor cells with reduced TAP expression, eliciting a polyclonal response.

Conclusions:

• Vaccination against TAP downregulation-induced antigens overcomes limitations of targeting unique tumor-resident neoantigens.
• This strategy represents a simpler and potentially more broadly applicable vaccination approach for most cancer patients.
• The findings suggest a promising new direction for cancer immunotherapy development.